Educational Sessions - Ballrooms A & B and Exhibit Hall D

Supported by an educational grant from Susan G. Komen for the Cure®

An update on advances in the technologies available for translational research.  Sessions are to provide people with a better understanding of the talks they hear using the techniques described.  They also provide researchers with a guide to the techniques they should be considering for their studies.

Treatment of Metastatic Breast Cancer – Breast Cancer as a Chronic Disease – Ballroom A

Moderator: Kathleen Pritchard, MD, FRCPC

ER positive

Kathleen Pritchard, MD, FRCPC

University of Toronto

Toronto, CANADA

Triple negative breast cancer

Vered Stearns, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, MD

HER2 positive

Ian E. Krop , MD, PhD

Dana-Farber Cancer Institute

Boston, MA

Mouse Models of PI3K-Dependent and Basal-Like Breast Cancer  - Ballroom B

Moderator: Carlos L. Arteaga, MD

Vanderbilt-Ingram Cancer Center

Vanderbilt University

Nashville, TN

PI3K mouse models of breast cancer

Ramon E. Parsons, MD, PhD

Institute for Cancer Genetics

Columbia University

New York, NY

Mouse models of basel-like breast cancer

Jos Jonkers, PhD

Netherlands Cancer Institute

Amsterdam, NETHERLANDS

Patient-derived xenograft models for preclinical breast cancer research: Not just basal anymore

Michael T. Lewis, PhD

Baylor College of Medicine

Houston, TX

Controversies in Early Breast Cancer – Exhibit Hall D

Moderator: Peter M. Ravdin, MD, PhD

UT Health Science Center San Antonio

San Antonio, TX

Controversies in early breast cancer: Small tumors

Peter M. Ravdin, MD, PhD

UT Health Science Center San Antonio

San Antonio, TX

Chemotherapy benefit in ER positive breast cancer - Mixed messages

Kathy Albain, MD, FACP

Loyola University Chicago Stritch School of Medicine

Maywood, IL

Adjuvant therapy in patients with a borderline HER-2 status

Angelo Di Leo, MD, PhD

Hospital of Prato

Prato, ITALY

New Technologies in Biomarker Discovery for the Clinician – Ballroom A

Moderator: Trey Westbrook, PhD

Baylor College of Medicine

Houston, TX

Metabolomics as a tool to study cancer progression

Arun Sreekumar, PhD

Baylor College of Medicine

Houston, TX

Proteomics

Gordon Mills, MD, PhD

UT MD Anderson Cancer Center

Houston, TX

The potential of epigenetic therapy in breast cancer

Stephen Baylin, MD

Johns Hopkins University

Baltimore, MD

Breast Cancer Trials in Developing Countries - Opportunities and Challenges – Ballroom B

Moderator: Ismail Jatoi, MD, PhD, FACS

UT Health Science Center San Antonio

San Antonio, TX

Challenges in the design and implementation of breast cancer clinical trials in developing countries

Sudeep Gupta, MD, DM

Tata Memorial Hospital

Mumbai, INDIA

Practicality, promise and pitfalls in industry-sponsored trials (in developing countries)

Sandra J. Horning, MD

Genentech, Inc.

South San Francisco, CA

Novel approach to breast cancer in low income countries

David J. Kerr, CBE, MA, MD, DSc FRCP (Glas & Lon), FRCGP (Hon), FMedSci

University of Oxford

Oxford, UNITED KINGDOM

Challenges in the Care of Special Populations with Breast Cancer – Exhibit Hall D

Moderator: Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

Oncofertility: Translation in multidimensions

Teresa K. Woodruff, PhD

Northwestern University

Chicago, IL

Treatment of young women with breast cancer

Ann H. Partridge, MD, MPH

Dana-Farber Cancer Institute

Boston, MA

Treatment of older women with breast cancer

Arti Hurria, MD

City of Hope

Duarte, CA

What Makes a Good Target? - Ballroom A

Moderator: Mark D. Pegram, MD

Miller School of Medicine of University of Miami
Miami, FL

Target, identification and drug discovery: What is druggable?

Stephen W. Fesik, PhD

Vanderbilt University Medical Center

Nashville, TN

Clinical validation of new therapeutic targets in breast cancer

Mark D. Pegram, MD

Miller School of Medicine of University of Miami

Miami, FL

Study design considerations in the development of drugs and the diagnostic tests that can guide their use

Steve Shak, MD

Genomic Health, Inc.

Hillsborough, CA

 

Reconstruction – Ballroom B

Moderator: Richard L. Crownover, MD, PhD

Cancer Therapy and Research Center at

UT Health Science Center San Antonio

San Antonio, TX

Breast reconstruction with implants and post-mastectomy irradiation: Algorithms and outcomes

Peter G. Cordeiro, MD, FACS

Memorial Sloan-Kettering Cancer Center

New York, NY

Strange bedfellows: Radiation therapy and breast reconstruction

Richard C. Zellars, MD

Johns Hopkins University

Baltimore, MD

Measuring outcomes in breast reconstruction: The patient perspective

Andrea L. Pusic, MD, MHS, FRCSC

Memorial Sloan-Kettering Cancer Center

New York, NY

Registration - Bridge Hall

Career Development Forum: A Networking Session for Young Investigators – Ballroom B

Networking and career development opportunities for early career scientists.   The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the SABCS. Space in the workshop is limited to 200 participants; registrations will be accepted on a first-come, first-served basis and is free of charge.

Opening Remarks - Exhibit Hall D

Plenary Lecture 1- Exhibit Hall D

Endocrine Therapy for Breast Cancer: Looking Into The Future

Eric P. Winer, MD

Dana-Farber Cancer Institute

Boston, MA

General Session 1 - Exhbit Hall D

Moderator: Kathy D. Miller, MD

Indiana University School of Medicine

Indianapolis, IN

AACR Distinguished Lectureship in Breast Cancer Research – Exhibit Hall D

Protective Adaptive Responses to Breast Cancer Therapies

Joan S. Brugge, PhD

Harvard Medical School

Boston, MA

Lunch

Product Theatre - Exhibit Hall C - Exhibit Area

Updates in Breast Cancer in Diagnostic Testing

Sponsored by Clarient, A GE Healthcare Company

Clinical Science Forum - Medical Economics - The Cost of Care - Ballroom A

Moderator: Eric P. Winer, MD

Dana-Farber Cancer Institute

Boston, MA

The cost of cancer care: How much do we spend and how can we spend it better?

Elena Elkin, PhD

Memorial Sloan-Kettering Cancer Center

New York, NY

Heatlh care reform and cost control:  Practical and ethical considerations for cancer care providers

Michasel Hassett, MD, MPH

Dana-Farber Cancer Institute

Boston, MA

Panel Discussion

Eric P. Winer, MD

Dana-Farber Cancer Institute

Boston, MA

Michael Hassett, MD, MPH

Dana-Farber Cancer Institute

Boston, MA

Elena Elkin, PhD

Memorial Sloan-Kettering Cancer Center

New York, NY

Basic Science Forum - Breast Cancer Initiation – Ballroom B

Moderator: Yi Li, PhD, MS

Baylor College o f Medicine

Houston, TX

P53, stem cells, and breast cancer

Geoffrey M. Wahl, PhD

Salk Institute for Biological Studies

La Jolla, CA

Stem and progenitor cells and breast cancer heterogeneity

Matthew Smalley, PhD

Breakthrough Breast Cancer Centre

Institute of Cancer Research

London, UNITED KINGDOM

Special Report - Breast Cancer and the Environment: A Life Course Approach - Report Release from an IOM Committee - Exhibit Hall D

Moderator: Amelie G. Ramirez, Dr. PH, MPH

UT Health Science Center San Antonio

San Antonio, TX

Irva Hertz-Picciotto, PhD, MPH

University of California, Davis

Davis, CA

and

Robert A. Hiatt, MD, PhD

University of California, San Francisco

San Francisco, CA

Product Theatre - Exhibit Hall C - Exhibit Area

A Unique Treatment Option for Chemotherapy Induced Nausea & Vomiting

Sponsored by Prostrakan, Inc.

General Session 2 - Exhibit Hall D

Moderator: Julie R. Gralow, MD

University of Washington

Seattle, WA

Susan G. Komen for the Cure® Brinker Awards for Scientific Distinction Lectures - Exhibit Hall D

Oncogenes & ER: A convenient marriage for hormone-dependent breast cancer

Carlos L. Arteaga, MD

Vanderbilt-Ingram Cancer Center

Vanderbilt University

Nashville, TN

Changes in the management of the axilla in breast cancer

Armando E. Giuliano, MD, FACS, FRCSEd

Cedars-Sinai Medical Center

Saul and Joyce Brandman Breast Center

Los Angeles, CA

Poster Session 1 - Exhibit Hall A-B 

Poster Discussion II: Local Therapy - Ballroom B

Registration - Bridge Hall

Poster Session 2 - Exhibit Halls A-B

Poster Discussion IV: Survivorship - Ballroom B

Plenary Lecture 2 - Exhibit Hall D

Macrophages as Novel Targets for Therapy in Breast Cancer

Lisa M. Coussens, PhD

University of California San Francisco

San Francisco, CA

General Session 3 - Exhibit Hall D

Moderator: Jose Baselga, MD, PhD

Massachusetts General Hospital

Boston, MA

William L. McGuire Memorial Lecture - Exhibit Hall D

Translating genomic insights into improved breast cancer management

Joe Gray, PhD

Oregon Health & Science University

Portland, OR

Product Theatre - Abraxane - Exhibit Hall C - Exhibit Area

Sponsored by Celgene Corporation

Case Discussion 1 - Ballroom A

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Basic Science Forum - Ballroom B

Estrogen Receptor

Moderator: Suzanne A.W. Fuqua, PhD

Baylor College of Medicine

Houston, TX

Steroid receptor cistromics

Myles Brown, MD

Dana-Farber Cancer Institute

Boston, MA

Nuclear receptor coactivators: Physiology and disease

Bert W. O'Malley, MD

Baylor College of Medicine

Houston, TX

Mini-Symposium 1 - Ballroom B

Tumor Heterogeneity and Metastasis

Moderator: Rachel Schiff, PhD

Baylor College of Medicine

Houston, TX

Imaging cancer invasion and experimental therapy response: How to overcome resistance niches

Peter Friedl, MD, PhD

Radboud University Nijmegen

HB Nijmegen, NETHERLANDS

Tumor-entrained neutrophils inhibit breast cancer metastasis seeding in the lung

Robert Benezra, PhD

Memorial Sloan-Kettering Cancer Center

New York, NY

Tumor heterogeneity and metastasis

Matthew J. Ellis, MB, BChir, PhD

Washington University School of Medicine

St. Louis, MO

Mini-Symposium 2 - Exhibit Hall D

Environmental Exposures, Epigenetics and Epidemiology

Moderator: Cheryl Lyn Walker, PhD

UT MD Anderson Cancer Center

Houston, TX

Epidemiology of preeclampsia and other early exposures on breast cancer risk

Michele R. Forman, PhD

UT Austin

Austin, TX

Environ exposures, epigenetics & epidemiology influence of environmental factors on pubertal maturation and breast cancer etiology

Robert A. Hiatt, MD, PhD

University of California, San Francisco

San Francisco, CA

Breast cancer and the environment: Developmental reprogramming of cancer susceptibility by early life environmental exposures

Cheryl Lyn Walker, PhD

UT MD Anderson Cancer Center

Houston, TX

General Session 4 - Exhibit Hall D

Moderator: Emiel JT Rutgers, MD, PhD

Netherlands Cancer Institute

Amsterdam, NETHERLANDS

Poster Session 3 - Exhibit Halls A-B

Registration - Bridge Hall

Poster Session 4 - Exhibit Halls A-B 

Poster Discussion VIII: Targeting Triple Negatives and Stem Cells - Ballroom B

Plenary Lecture 3 - Exhibit Hall D

Advances in Axillary Surgery: Sentinel Nodes and Beyond

Barbara L. Smith, MD, PhD

Massachusetts General Hospital

Boston, MA

General Session 5 - Exhibit Hall D

Moderator: Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

AACR Outstanding Investigator Award for Breast Cancer Research , funding by Susan G. Komen for the Cure® – Exhibit Hall D

Alteration and Inhibition of PTEN in Breast Cancer

Ramon E. Parsons, MD, PhD

Columbia University

New York, NY

Lunch

Product Theatre - Abraxane - Exhibit Hall C - Exhibit Area

Sponsored by Celgene Corporation

Case Discussion 2 - Ballroom A

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Basic Science Forum – Ballroom B

Tumor Microenvironment

Moderator: Rong Li, PhD

UT Health Science Center San Antonio

San Antonio, TX

Extrinsic and intrinsic force regulation of breast cancer progression and treatment

Valerie M. Weaver, PhD

University of California San Francisco
San Francisco, CA

COX-2 dependent collagen fibrillogenesis drives metastasis in the postpartum involuting mammary gland

Pepper J. Schedin, PhD

University of Colorado Denver

Aurora, CO

Mini-Symposium 3 - Ballroom B

Metabolism in Breast Cancer - Metabolomics

Moderator: Michael Pollak, MD
McGill University
Montreal, CANADA

Adiposity, metabolism, and risk of breast cancer

Susan E. Hankinson, ScD

Harvard Medical School

Boston, MA

HIF-1, metabolism, and metastasis

Gregg L. Semenza, MD, PhD

The Johns Hopkins University School of Medicine

Baltimore, MD

Energy metabolism in breast cancer: Translational science insights relevant to effects of diet, exercise, and metformin on risk and prognosis

Michael Pollak, MD

McGill University

Montreal, CANADA

Mini-Symposium 4 - Exhibit Hall D

The Role and Promise of Neoadjuvant Therapy in Breast Cancer

Moderator: Lisa A. Carey, MD, ScM

University of North Carolina

Chapel, NC

The neoadjuvant setting, HER2-driven and triple negative breast cancer

Lisa A. Carey, MD, ScM

University of North Carolina

Chapel Hill, NC

Preoperative endocrine therapy: New approaches

Ian Smith, MD

Royal Marsden Hospital

London, UNITED KINGDOM

Interface with radiation oncology

Thomas A. Buchholz , MD

UT MD Anderson Cancer Center

Houston, TX

Neoadjuvant trials as a discovery tool

Carlos L. Arteaga, MD

Vanderbilt-Ingram Cancer Center

Vanderbilt University

Nashville, TN

General Session 6 - Exhibit Hall D

Moderator: Pamela Goodwin, MD

Mount Sinai Hospital

Toronto, CANADA

Poster Session 5 - Exhibit Halls A-B 

Poster Discussion X: Tumor Suppressors/DNA Repair - Ballroom B

Registration - Bridge Hall

Genome Data for the Masses: Presentation of TCGA and IGC Breast Tumor Data

Moderator: Charles M. Perou, PhD

University of North Carolina

Chapel Hill, NC

and

Michael Stratton, FRCPath, FMCDSCI, FRS

The Wellcome Trust Sanger Institute

Hinxton, Cambridge, UNITED KINGDOM

TCGA breast cancer sequencing: Results and interpretation

Elaine R. Mardis, PhD

Washington University

St. Louis, MO

 

Diverse patterns of mutation in breast cancer genomes

Michael Stratton, FRCPath, FMCDSCI, FRS

The Wellcome Trust Sanger Institute

Hinxton, Cambridge, UNITED KINGDOM

Integrative genomic analyses of breast cancer from The Cancer Genome Atlas (TCGA)

Chad J. Creighton, PhD

Baylor College of Medicine

Houston, TX

Epigenomic data analysis of TCGA breast cancer samples

Peter W. Laird, PhD

USC Epigenome Center

Los Angeles, CA

The DNA copy number landscapes and genomic architecture: Relevance for progression and outcome

Anne-Lise Børresen-Dale, PhD, MD (h.c.)

Oslo University Hospital

Oslo, NORWAY

Genomic analyzes for pathway characterization

David Haussler, PhD

University of California, Santa Cruz

Santa Cruz, CA

The Year in Review - Exhibit Hall D

Moderator: C. Kent Osborne, MD

Baylor College of Medicine

Houston, TX

Advances in basic breast cancer research

Kornelia Polyak, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

Translational breast cancer research

Andrea Richardson, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

Early breast cancer

Nancy E. Davidson, MD

University of Pittsburgh Cancer Institute

Pittsburgh, PA

Challenges and success: Treatment of metastatic breast cancer 2011

Hope S. Rugo, MD

University of California, San Francisco

San Francisco, CA